Erlotinib

Lung Cancer Therapies Market to Amplify Significantly over 2022-2029 - Brandessence Market Research

Retrieved on: 
Monday, May 29, 2023
Smoker, Atezolizumab, Complex conjugate, Lung cancer, Tobacco, Alectinib, Cough, Hospital, Acquisition, Patient, Investment, EGFR, Diffuse large B-cell lymphoma, Risk, Eli Lilly and Company, Spacecraft, Health, Air pollution, Virus, Disease, ALK, Therapy, Crizotinib, Entrectinib, Research, Paclitaxel, Boehringer Ingelheim, ARIAD Pharmaceuticals, Growth, Pembrolizumab, Smoking, Erlotinib, Docetaxel, Gas, Cancer, Osimertinib, Chest pain, Traction, Blood, Immune system, ROS1, Trastuzumab emtansine, Teva Pharmaceuticals, Radiation, Pfizer, Bristol Myers Squibb, AstraZeneca, Lung, Novartis, Smoke, Nivolumab, Pharmaceutical industry, Renewable energy, Vaccine, Bayer, Genentech, Talimogene laherparepvec

With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.

Key Points: 
  • With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.
  • The business intelligence report on Lung Cancer Therapies Market by Brandessence Market Research is curated with an aim to provide the industry participants with a succulent overview of this industry.
  • By treatment, the chemotherapy segment is projected to amass notable gains due to its efficacy in treating lung cancer.
  • The Lung Cancer Therapies Market is anticipated to garner significant returns over the estimated timeline of 2022-2029.

Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies

Retrieved on: 
Thursday, January 5, 2023
Precision medicine, Stritch School of Medicine, Druggability, NCI, Trastuzumab, Rituximab, SAN, Loyola University, Patient, Frontier, AI, Safety, GTP, Internal medicine, IND, Erlotinib, National Cancer Institute, Proteome, Cedars-Sinai Medical Center, Pharmaceutical industry, Genentech, Development

SOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company advancing transformative drugs against historically undruggable disease-causing targets, announced the selection of its first development candidate, FMC-376, an oral, covalent small-molecule inhibitor that selectively targets both active (GTP-bound) and inactive (GDP-bound) conformations of KRASG12C. In preclinical studies, FMC-376 retains potency in the context of receptor tyrosine kinase activation, which is likely a major mechanism of non-response and resistance to prior generation inhibitors that only target inactive (GDP-bound) KRASG12C. Preclinical data for FMC-376 supports a potential best-in-class profile for safety and efficacy, with the promise of first-line treatment in both monotherapy and combination use. IND filing for FMC-376 is planned for this year.

Key Points: 
  • Preclinical data for FMC-376 supports a potential best-in-class profile for safety and efficacy, with the promise of first-line treatment in both monotherapy and combination use.
  • Dr. Klein has more than 20 years of oncology drug development experience across industry and academia.
  • At Genentech, Dr. Klein led development and medical affairs for a portfolio of oncology programs including trastuzumab (Herceptin), rituximab (Rituxan), pertuzumab (Perjeta) and erlotinib (Tarceva).
  • She trained in internal medicine at Cedars-Sinai Medical Center and Oncology at the NCI, serving as chief oncology fellow during that time.

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

Retrieved on: 
Thursday, September 1, 2022
Pharmacia, Neoplasm, COVID-19, CEO, Technology, Cancer prevention, Cancer, XV, Research, Squamous cell carcinoma, Alpha Sigma Tau, Therapy, Pfizer, Private Securities Litigation Reform Act, Xi, Risk, OSI, Hope, SEC, U.S. Securities and Exchange Commission, McGill University, 100,000, GLOBE, Nasdaq, Erlotinib, Chief commercial officer, Annual report, Marketing, OSI Pharmaceuticals, Vii, Alpha Tau Delta, Bristol Myers Squibb, Patient, Pharmaceutical industry, Tel Aviv University, Alpha

JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Companys Board of Directors in order to assume the full-time position of Alpha Taus Chief Commercial Officer.

Key Points: 
  • JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Companys Board of Directors in order to assume the full-time position of Alpha Taus Chief Commercial Officer.
  • Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure for the launch of Novocures Optune product.
  • Prior to OSI, Mr. Melnyk was executive director of oncology at Pfizer and Pharmacia and a director of oncology at Bristol-Myers Squibb.
  • We are thrilled to bring Peter in to lead our commercialization efforts, said Alpha Tau CEO Uzi Sofer.

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Retrieved on: 
Tuesday, July 20, 2021
Organic compounds, Chemical compounds, Quinazolines, Tyrosine kinase receptors, Amines, Astellas Pharma, Erlotinib, Ethers, Epidermal growth factor receptor, Chemistry

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.

Key Points: 
  • NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.
  • Both product candidates are exclusively licensed forU.S.commercialization withGalderma Holding SA.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference

Retrieved on: 
Thursday, May 27, 2021
Organ systems, Acneiform eruptions, Cutaneous conditions, Organic compounds, Food and Drug Administration, Pharmaceuticals policy, Prescription Drug User Fee Act, Rosacea, Acne, Erlotinib

Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for the development of TWYNEO, under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021.

Key Points: 
  • Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for the development of TWYNEO, under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021.
  • Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Wednesday, February 24, 2021
Organic compounds, Branches of biology, Quinazolines, Chemical compounds, Amines, Astellas Pharma, Erlotinib, Ethers, Epidermal growth factor receptor, Growth factor receptor inhibitor

Available on demand to conference participants.

Key Points: 
  • Available on demand to conference participants.
  • A webcast replay of the presentation at H.C. Wainwright Life Sciences Conference will be available in the Investors/Events and Presentations section of the Companys website at www.sol-gel.com for 30 days.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

Retrieved on: 
Wednesday, December 2, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Organic compounds, Chemical compounds, Quinazolines, Amines, Aromatic compounds, Chloroarenes, Tyrosine kinase inhibitors, Erlotinib, Ethers, T790M, Gefitinib, Epidermal growth factor receptor

The European Board of Appeals announced its decision at a hearing on December 1st, rejecting the opposition of EP Patent 1848414 initiated by a Boehringer Ingelheim entity.

Key Points: 
  • The European Board of Appeals announced its decision at a hearing on December 1st, rejecting the opposition of EP Patent 1848414 initiated by a Boehringer Ingelheim entity.
  • The EP Patent 1848414 originally granted in April 2011 covers the use of irreversible EGFR inhibitors in treating gefitinib and/or erlotinib resistant cancer and cancer with a T790M EGFR mutation.
  • On November 28, 2011, an opposition was filed seeking invalidation of the patent.
  • At a final hearing, the Board of Appeals announced its decision, concluding that the opposition was inadmissible and reversing the European Opposition Division decision issued in 2014, thereby upholding the EP Patent 1848414 as originally granted.

Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020

Retrieved on: 
Monday, November 9, 2020
Organ systems, Dermatology, Acneiform eruptions, Cutaneous conditions, Integumentary system, Papulopustular, Amines, Quinazolines, Rosacea, Acne, Erlotinib, Epidermal growth factor receptor

Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of papulopustular rosacea.

Key Points: 
  • Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of papulopustular rosacea.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020

Retrieved on: 
Wednesday, November 4, 2020
Health sciences, Organ systems, Medicine, Acneiform eruptions, Rosacea, Erlotinib, Topical medication, Papulopustular

NESS ZIONA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report third quarter 2020 financial results on Thursday, November 12, 2020 at 7:05 AM ET.

Key Points: 
  • NESS ZIONA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report third quarter 2020 financial results on Thursday, November 12, 2020 at 7:05 AM ET.
  • Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of papulopustular rosacea.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020

Retrieved on: 
Wednesday, July 29, 2020
Health, Organ systems, RTT, Acneiform eruptions, Rosacea, Erlotinib, Topical medication, Papulopustular

NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2020 financial results on Thursday, August 6, 2020 at 7:05 AM ET.

Key Points: 
  • NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2020 financial results on Thursday, August 6, 2020 at 7:05 AM ET.
  • Sol-Gelis a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.Sol-Gelleverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .